Dihydroartemisinin enhances radiosensitivity of human glioma cells in vitro
Authors:
- 5 November 2005
- journal article
- research article
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 132 (2) , 129-135
Abstract
Purpose: The antimalarial agent, artemisinin, also confers cancer-specific cytotoxic effects by reacting with ferrous iron atoms to form free radicals. Here, we investigated the radiosensitizing effects of dihydroartemisinin on glioma cells and assessed some possible mechanisms for these effects. Materials and methods: U373MG glioma cells treated with various concentrations of dihydroartemisinin plus radiation, and efficiency of radiosensitization was assessed by clonogenic survival assay. Expression and activity of antioxidant enzymes, glutathione-S-transferase (GST) were quantified by western blot and enzymatic activity analyses, respectively. Results: Dihydroartemisinin showed higher cytotoxicity in the glioma cell lines than in the liver, breast or cervical cancer cell lines. In clonogenic survival assays, treatment with dihydroartemisinin alone dose-dependently reduced the number of U373MG colonies, while treatment with dihydroartemisinin plus γ-irradiation showed far lower clonal survival than cultures treated with radiation or dihydroartemisinin alone. The radiosensitizing effect of dihydroartemisinin was blocked significantly by the free radical scavengers, NAC and TIRON, indicating association with dihydroartemisinin-induced ROS generation. In addition, the radiation-induced expression of endogenous GST was suppressed by treatment with dihydroartemisinin. The radiosensitizing effect of dihydroartemisinin was also markedly enhanced by the addition of holotransferrin Conclusion: Taken together, our results strongly suggest that dihydroartemisinin triggers production of ROS and inhibits GST activity, leading to effective and therapeutically relevant radiosensitization of human glioma cells.Keywords
This publication has 28 references indexed in Scilit:
- Effects of artemisinin-tagged holotransferrin on cancer cellsLife Sciences, 2005
- Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunateBiochemical Pharmacology, 2004
- Artemisinin drugs in the treatment of malaria: from medicinal herb to registered medicationTrends in Pharmacological Sciences, 1999
- Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrinCancer Letters, 1995
- Role of intracellular SOD in protecting human leukemic and cancer cells against superoxide and radiationFree Radical Biology and Medicine, 1994
- Transferrin receptor in normal and neoplastic brain tissue: implications for brain-tumor immunotherapyJournal of Neurosurgery, 1990
- National survey of patterns of care for brain-tumor patientsJournal of Neurosurgery, 1989
- Transferrin receptor molecules in human cell lines derived from the CNS malignant gliomas: Immunohistochemical and flow-cytometric study.ACTA HISTOCHEMICA ET CYTOCHEMICA, 1989
- Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxinJournal of Neurosurgery, 1987
- Qinghaosu (Artemisinin): an Antimalarial Drug from ChinaScience, 1985